PMC:7445716 / 73149-74338 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T628","span":{"begin":331,"end":353},"obj":"Body_part"},{"id":"T629","span":{"begin":474,"end":491},"obj":"Body_part"},{"id":"T630","span":{"begin":486,"end":491},"obj":"Body_part"},{"id":"T631","span":{"begin":495,"end":505},"obj":"Body_part"},{"id":"T632","span":{"begin":530,"end":545},"obj":"Body_part"},{"id":"T633","span":{"begin":555,"end":569},"obj":"Body_part"},{"id":"T634","span":{"begin":588,"end":610},"obj":"Body_part"},{"id":"T635","span":{"begin":1105,"end":1113},"obj":"Body_part"}],"attributes":[{"id":"A628","pred":"fma_id","subj":"T628","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A629","pred":"fma_id","subj":"T629","obj":"http://purl.org/sig/ont/fma/fma66772"},{"id":"A630","pred":"fma_id","subj":"T630","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A631","pred":"fma_id","subj":"T631","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A632","pred":"fma_id","subj":"T632","obj":"http://purl.org/sig/ont/fma/fma77626"},{"id":"A633","pred":"fma_id","subj":"T633","obj":"http://purl.org/sig/ont/fma/fma63820"},{"id":"A634","pred":"fma_id","subj":"T634","obj":"http://purl.org/sig/ont/fma/fma55675"},{"id":"A635","pred":"fma_id","subj":"T635","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"COVID-19 pandemic prompts all efforts for the early recognition and treatment of its manifestations. In analogy to other viruses, belonging or not to the coronavirus family [63, 67], neurologic complications in COVID-19 are emerging as one of the most significant clinical chapters of this pandemic. In this regard, peripheral and central nervous system damage in COVID-19 has been postulated to be the consequence of two different mechanisms: 1) hematogenous (infection of endothelial cells or leucocytes) or trans-neuronal (via olfactory tract or other cranial nerves) dissemination to central nervous system in relation with viral neurotropism, and 2) abnormal immune-mediated response causing secondary neurological involvement [62, 68, 69]. The first mechanism is supposed to be responsible for the most common neurological symptoms developed by patients with COVID-19 (e.g., hypogeusia, hyposmia, headache, vertigo, and dizziness). In contrast, the second can lead to severe complications during or after the course of the illness, either dysimmune (e.g., myelitis, encephalitis, GBS) or induced by cytokine overproduction (hypercoagulable state and cerebrovascular events) [68, 69]."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T242","span":{"begin":331,"end":353},"obj":"Body_part"},{"id":"T243","span":{"begin":339,"end":353},"obj":"Body_part"},{"id":"T244","span":{"begin":530,"end":545},"obj":"Body_part"},{"id":"T245","span":{"begin":555,"end":569},"obj":"Body_part"},{"id":"T246","span":{"begin":588,"end":610},"obj":"Body_part"},{"id":"T247","span":{"begin":596,"end":610},"obj":"Body_part"}],"attributes":[{"id":"A242","pred":"uberon_id","subj":"T242","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"A243","pred":"uberon_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/UBERON_0001016"},{"id":"A244","pred":"uberon_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/UBERON_0002265"},{"id":"A245","pred":"uberon_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/UBERON_0001785"},{"id":"A246","pred":"uberon_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"A247","pred":"uberon_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/UBERON_0001016"}],"text":"COVID-19 pandemic prompts all efforts for the early recognition and treatment of its manifestations. In analogy to other viruses, belonging or not to the coronavirus family [63, 67], neurologic complications in COVID-19 are emerging as one of the most significant clinical chapters of this pandemic. In this regard, peripheral and central nervous system damage in COVID-19 has been postulated to be the consequence of two different mechanisms: 1) hematogenous (infection of endothelial cells or leucocytes) or trans-neuronal (via olfactory tract or other cranial nerves) dissemination to central nervous system in relation with viral neurotropism, and 2) abnormal immune-mediated response causing secondary neurological involvement [62, 68, 69]. The first mechanism is supposed to be responsible for the most common neurological symptoms developed by patients with COVID-19 (e.g., hypogeusia, hyposmia, headache, vertigo, and dizziness). In contrast, the second can lead to severe complications during or after the course of the illness, either dysimmune (e.g., myelitis, encephalitis, GBS) or induced by cytokine overproduction (hypercoagulable state and cerebrovascular events) [68, 69]."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T668","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T669","span":{"begin":211,"end":219},"obj":"Disease"},{"id":"T670","span":{"begin":364,"end":372},"obj":"Disease"},{"id":"T671","span":{"begin":461,"end":470},"obj":"Disease"},{"id":"T672","span":{"begin":865,"end":873},"obj":"Disease"},{"id":"T673","span":{"begin":1062,"end":1070},"obj":"Disease"},{"id":"T674","span":{"begin":1072,"end":1084},"obj":"Disease"},{"id":"T675","span":{"begin":1086,"end":1089},"obj":"Disease"},{"id":"T676","span":{"begin":1130,"end":1145},"obj":"Disease"}],"attributes":[{"id":"A668","pred":"mondo_id","subj":"T668","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A669","pred":"mondo_id","subj":"T669","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A670","pred":"mondo_id","subj":"T670","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A671","pred":"mondo_id","subj":"T671","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A672","pred":"mondo_id","subj":"T672","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A673","pred":"mondo_id","subj":"T673","obj":"http://purl.obolibrary.org/obo/MONDO_0002565"},{"id":"A674","pred":"mondo_id","subj":"T674","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A675","pred":"mondo_id","subj":"T675","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A676","pred":"mondo_id","subj":"T676","obj":"http://purl.obolibrary.org/obo/MONDO_0002305"}],"text":"COVID-19 pandemic prompts all efforts for the early recognition and treatment of its manifestations. In analogy to other viruses, belonging or not to the coronavirus family [63, 67], neurologic complications in COVID-19 are emerging as one of the most significant clinical chapters of this pandemic. In this regard, peripheral and central nervous system damage in COVID-19 has been postulated to be the consequence of two different mechanisms: 1) hematogenous (infection of endothelial cells or leucocytes) or trans-neuronal (via olfactory tract or other cranial nerves) dissemination to central nervous system in relation with viral neurotropism, and 2) abnormal immune-mediated response causing secondary neurological involvement [62, 68, 69]. The first mechanism is supposed to be responsible for the most common neurological symptoms developed by patients with COVID-19 (e.g., hypogeusia, hyposmia, headache, vertigo, and dizziness). In contrast, the second can lead to severe complications during or after the course of the illness, either dysimmune (e.g., myelitis, encephalitis, GBS) or induced by cytokine overproduction (hypercoagulable state and cerebrovascular events) [68, 69]."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T652","span":{"begin":121,"end":128},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T653","span":{"begin":331,"end":353},"obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"T654","span":{"begin":331,"end":353},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T655","span":{"begin":331,"end":353},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"},{"id":"T656","span":{"begin":373,"end":376},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T657","span":{"begin":474,"end":491},"obj":"http://purl.obolibrary.org/obo/CL_0000115"},{"id":"T658","span":{"begin":495,"end":505},"obj":"http://purl.obolibrary.org/obo/CL_0000738"},{"id":"T659","span":{"begin":563,"end":569},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T660","span":{"begin":588,"end":610},"obj":"http://purl.obolibrary.org/obo/UBERON_0001017"},{"id":"T661","span":{"begin":588,"end":610},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T662","span":{"begin":588,"end":610},"obj":"http://www.ebi.ac.uk/efo/EFO_0000908"}],"text":"COVID-19 pandemic prompts all efforts for the early recognition and treatment of its manifestations. In analogy to other viruses, belonging or not to the coronavirus family [63, 67], neurologic complications in COVID-19 are emerging as one of the most significant clinical chapters of this pandemic. In this regard, peripheral and central nervous system damage in COVID-19 has been postulated to be the consequence of two different mechanisms: 1) hematogenous (infection of endothelial cells or leucocytes) or trans-neuronal (via olfactory tract or other cranial nerves) dissemination to central nervous system in relation with viral neurotropism, and 2) abnormal immune-mediated response causing secondary neurological involvement [62, 68, 69]. The first mechanism is supposed to be responsible for the most common neurological symptoms developed by patients with COVID-19 (e.g., hypogeusia, hyposmia, headache, vertigo, and dizziness). In contrast, the second can lead to severe complications during or after the course of the illness, either dysimmune (e.g., myelitis, encephalitis, GBS) or induced by cytokine overproduction (hypercoagulable state and cerebrovascular events) [68, 69]."}

LitCovid-PubTator

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T440","span":{"begin":0,"end":100},"obj":"Sentence"},{"id":"T441","span":{"begin":101,"end":299},"obj":"Sentence"},{"id":"T442","span":{"begin":300,"end":443},"obj":"Sentence"},{"id":"T443","span":{"begin":444,"end":745},"obj":"Sentence"},{"id":"T444","span":{"begin":746,"end":937},"obj":"Sentence"},{"id":"T445","span":{"begin":938,"end":1189},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"COVID-19 pandemic prompts all efforts for the early recognition and treatment of its manifestations. In analogy to other viruses, belonging or not to the coronavirus family [63, 67], neurologic complications in COVID-19 are emerging as one of the most significant clinical chapters of this pandemic. In this regard, peripheral and central nervous system damage in COVID-19 has been postulated to be the consequence of two different mechanisms: 1) hematogenous (infection of endothelial cells or leucocytes) or trans-neuronal (via olfactory tract or other cranial nerves) dissemination to central nervous system in relation with viral neurotropism, and 2) abnormal immune-mediated response causing secondary neurological involvement [62, 68, 69]. The first mechanism is supposed to be responsible for the most common neurological symptoms developed by patients with COVID-19 (e.g., hypogeusia, hyposmia, headache, vertigo, and dizziness). In contrast, the second can lead to severe complications during or after the course of the illness, either dysimmune (e.g., myelitis, encephalitis, GBS) or induced by cytokine overproduction (hypercoagulable state and cerebrovascular events) [68, 69]."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T784","span":{"begin":881,"end":891},"obj":"Phenotype"},{"id":"T785","span":{"begin":893,"end":901},"obj":"Phenotype"},{"id":"T786","span":{"begin":903,"end":911},"obj":"Phenotype"},{"id":"T787","span":{"begin":913,"end":920},"obj":"Phenotype"},{"id":"T788","span":{"begin":926,"end":935},"obj":"Phenotype"},{"id":"T789","span":{"begin":1062,"end":1070},"obj":"Phenotype"},{"id":"T790","span":{"begin":1072,"end":1084},"obj":"Phenotype"}],"attributes":[{"id":"A784","pred":"hp_id","subj":"T784","obj":"http://purl.obolibrary.org/obo/HP_0000224"},{"id":"A785","pred":"hp_id","subj":"T785","obj":"http://purl.obolibrary.org/obo/HP_0004409"},{"id":"A786","pred":"hp_id","subj":"T786","obj":"http://purl.obolibrary.org/obo/HP_0002315"},{"id":"A787","pred":"hp_id","subj":"T787","obj":"http://purl.obolibrary.org/obo/HP_0002321"},{"id":"A788","pred":"hp_id","subj":"T788","obj":"http://purl.obolibrary.org/obo/HP_0002321"},{"id":"A789","pred":"hp_id","subj":"T789","obj":"http://purl.obolibrary.org/obo/HP_0012486"},{"id":"A790","pred":"hp_id","subj":"T790","obj":"http://purl.obolibrary.org/obo/HP_0002383"}],"text":"COVID-19 pandemic prompts all efforts for the early recognition and treatment of its manifestations. In analogy to other viruses, belonging or not to the coronavirus family [63, 67], neurologic complications in COVID-19 are emerging as one of the most significant clinical chapters of this pandemic. In this regard, peripheral and central nervous system damage in COVID-19 has been postulated to be the consequence of two different mechanisms: 1) hematogenous (infection of endothelial cells or leucocytes) or trans-neuronal (via olfactory tract or other cranial nerves) dissemination to central nervous system in relation with viral neurotropism, and 2) abnormal immune-mediated response causing secondary neurological involvement [62, 68, 69]. The first mechanism is supposed to be responsible for the most common neurological symptoms developed by patients with COVID-19 (e.g., hypogeusia, hyposmia, headache, vertigo, and dizziness). In contrast, the second can lead to severe complications during or after the course of the illness, either dysimmune (e.g., myelitis, encephalitis, GBS) or induced by cytokine overproduction (hypercoagulable state and cerebrovascular events) [68, 69]."}

LitCovid-PMC-OGER-BB

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1110","span":{"begin":0,"end":8},"obj":"SP_7"},{"id":"T1111","span":{"begin":121,"end":128},"obj":"NCBITaxon:10239"},{"id":"T1112","span":{"begin":154,"end":165},"obj":"NCBITaxon:11118"},{"id":"T1113","span":{"begin":183,"end":193},"obj":"UBERON:0001016"},{"id":"T1114","span":{"begin":211,"end":219},"obj":"SP_7"},{"id":"T1115","span":{"begin":316,"end":326},"obj":"UBERON:0000010"},{"id":"T1116","span":{"begin":331,"end":353},"obj":"UBERON:0001017"},{"id":"T1117","span":{"begin":364,"end":372},"obj":"SP_7"},{"id":"T1118","span":{"begin":474,"end":485},"obj":"UBERON:0001986;CL:0000115"},{"id":"T1119","span":{"begin":486,"end":491},"obj":"CL:0000115"},{"id":"T1120","span":{"begin":495,"end":505},"obj":"CL:0000738"},{"id":"T1121","span":{"begin":516,"end":524},"obj":"CL:0000540"},{"id":"T1122","span":{"begin":530,"end":539},"obj":"GO:0007608;UBERON:0002265"},{"id":"T1123","span":{"begin":540,"end":545},"obj":"UBERON:0002265"},{"id":"T1124","span":{"begin":555,"end":569},"obj":"UBERON:0001785"},{"id":"T1125","span":{"begin":588,"end":610},"obj":"UBERON:0001017"},{"id":"T1126","span":{"begin":628,"end":633},"obj":"NCBITaxon:10239"},{"id":"T1127","span":{"begin":664,"end":670},"obj":"UBERON:0002405"},{"id":"T1128","span":{"begin":707,"end":719},"obj":"UBERON:0001016"},{"id":"T1129","span":{"begin":816,"end":828},"obj":"UBERON:0001016"},{"id":"T1130","span":{"begin":865,"end":873},"obj":"SP_7"},{"id":"T1131","span":{"begin":1156,"end":1171},"obj":"UBERON:0002037"}],"text":"COVID-19 pandemic prompts all efforts for the early recognition and treatment of its manifestations. In analogy to other viruses, belonging or not to the coronavirus family [63, 67], neurologic complications in COVID-19 are emerging as one of the most significant clinical chapters of this pandemic. In this regard, peripheral and central nervous system damage in COVID-19 has been postulated to be the consequence of two different mechanisms: 1) hematogenous (infection of endothelial cells or leucocytes) or trans-neuronal (via olfactory tract or other cranial nerves) dissemination to central nervous system in relation with viral neurotropism, and 2) abnormal immune-mediated response causing secondary neurological involvement [62, 68, 69]. The first mechanism is supposed to be responsible for the most common neurological symptoms developed by patients with COVID-19 (e.g., hypogeusia, hyposmia, headache, vertigo, and dizziness). In contrast, the second can lead to severe complications during or after the course of the illness, either dysimmune (e.g., myelitis, encephalitis, GBS) or induced by cytokine overproduction (hypercoagulable state and cerebrovascular events) [68, 69]."}

2_test

{"project":"2_test","denotations":[{"id":"32840686-24619619-63205809","span":{"begin":177,"end":179},"obj":"24619619"},{"id":"32840686-32518150-63205810","span":{"begin":732,"end":734},"obj":"32518150"},{"id":"32840686-32518172-63205811","span":{"begin":736,"end":738},"obj":"32518172"},{"id":"32840686-32860084-63205812","span":{"begin":740,"end":742},"obj":"32860084"},{"id":"32840686-32518172-63205813","span":{"begin":1180,"end":1182},"obj":"32518172"},{"id":"32840686-32860084-63205814","span":{"begin":1184,"end":1186},"obj":"32860084"}],"text":"COVID-19 pandemic prompts all efforts for the early recognition and treatment of its manifestations. In analogy to other viruses, belonging or not to the coronavirus family [63, 67], neurologic complications in COVID-19 are emerging as one of the most significant clinical chapters of this pandemic. In this regard, peripheral and central nervous system damage in COVID-19 has been postulated to be the consequence of two different mechanisms: 1) hematogenous (infection of endothelial cells or leucocytes) or trans-neuronal (via olfactory tract or other cranial nerves) dissemination to central nervous system in relation with viral neurotropism, and 2) abnormal immune-mediated response causing secondary neurological involvement [62, 68, 69]. The first mechanism is supposed to be responsible for the most common neurological symptoms developed by patients with COVID-19 (e.g., hypogeusia, hyposmia, headache, vertigo, and dizziness). In contrast, the second can lead to severe complications during or after the course of the illness, either dysimmune (e.g., myelitis, encephalitis, GBS) or induced by cytokine overproduction (hypercoagulable state and cerebrovascular events) [68, 69]."}

PMC:7445716 / 73149-74338 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7445716 / 73149-74338 JSON TXT